Endo International PLC (ENDP) Receives $15.32 Consensus Price Target from Analysts

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) has earned a consensus recommendation of “Hold” from the twenty-three brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $15.32.

A number of equities analysts have commented on the stock. TheStreet downgraded shares of Endo International from a “c-” rating to a “d+” rating in a report on Tuesday. Stifel Nicolaus boosted their target price on shares of Endo International from $10.00 to $17.00 and gave the stock a “hold” rating in a report on Thursday, August 9th. BMO Capital Markets boosted their target price on shares of Endo International from $9.00 to $16.00 and gave the stock a “market perform” rating in a report on Friday, August 10th. They noted that the move was a valuation call. Cantor Fitzgerald set a $12.00 target price on shares of Endo International and gave the stock a “hold” rating in a report on Wednesday, August 8th. Finally, Cowen reiterated a “hold” rating and issued a $9.00 target price on shares of Endo International in a report on Friday, November 9th.

In other news, Director Nancy J. Hutson sold 10,000 shares of the business’s stock in a transaction dated Thursday, November 15th. The stock was sold at an average price of $12.83, for a total transaction of $128,300.00. Following the sale, the director now owns 49,970 shares in the company, valued at $641,115.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.80% of the stock is currently owned by insiders.

Several hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp grew its stake in shares of Endo International by 2.7% during the third quarter. Bank of New York Mellon Corp now owns 2,513,250 shares of the company’s stock worth $42,299,000 after acquiring an additional 66,398 shares during the last quarter. Panagora Asset Management Inc. grew its stake in shares of Endo International by 10,718.5% during the third quarter. Panagora Asset Management Inc. now owns 1,775,205 shares of the company’s stock worth $29,877,000 after acquiring an additional 1,758,796 shares during the last quarter. Teachers Advisors LLC grew its stake in shares of Endo International by 230.1% during the third quarter. Teachers Advisors LLC now owns 1,468,025 shares of the company’s stock worth $24,707,000 after acquiring an additional 1,023,350 shares during the last quarter. Diamond Hill Capital Management Inc. grew its stake in shares of Endo International by 1.0% during the second quarter. Diamond Hill Capital Management Inc. now owns 1,100,259 shares of the company’s stock worth $10,375,000 after acquiring an additional 10,600 shares during the last quarter. Finally, Schroder Investment Management Group grew its stake in shares of Endo International by 78.1% during the second quarter. Schroder Investment Management Group now owns 747,571 shares of the company’s stock worth $7,349,000 after acquiring an additional 327,775 shares during the last quarter.

Shares of ENDP stock traded down $0.12 on Monday, hitting $12.03. The stock had a trading volume of 2,760,847 shares, compared to its average volume of 4,463,323. The company has a market capitalization of $2.73 billion, a P/E ratio of 3.13, a PEG ratio of 4.45 and a beta of 0.65. Endo International has a one year low of $5.27 and a one year high of $18.50.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Thursday, November 8th. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.12. The firm had revenue of $745.00 million during the quarter, compared to the consensus estimate of $694.93 million. Endo International had a positive return on equity of 1,348.52% and a negative net margin of 37.82%. The firm’s quarterly revenue was down 5.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.91 earnings per share. On average, analysts predict that Endo International will post 2.73 EPS for the current year.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Featured Story: What are the economic characteristics of a bear market?

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit